Schneider, J. S. http://orcid.org/0000-0002-4565-146X
Article History
Received: 8 April 2021
Revised: 12 May 2021
Accepted: 14 May 2021
First Online: 26 May 2021
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: Research performed by J.S.S. has been funded by Qilu Pharmaceutical Co., Ltd. and Fidia Pharmaceutical Corp, companies with a commercial interest in GM1 ganglioside. The funders had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of any manuscripts that emanated from funded projects.The author is a named inventor on a patent entitled, “Gene Therapies for Neurodegenerative Disorders Targeting Ganglioside Biosynthetic Pathways”, US Patent 10,874,749, assigned to Thomas Jefferson University.